The antibody-drug conjugate trastuzumab deruxtecan (T-DXd) showed promising activity in multiple non-breast/non-gastric cancer types with heavily pretreated HER2-expressing or HER2-mutant solid tumors, according to a recent study published in Cancer Discovery.1
More specifically, the T-DXd combination showed even greater antitumor activity in patients with HER2-mutant non-small cell lung cancer (NSCLC).
“HER2-targeted therapies have proven successful for patients with breast and gastric cancers; however, there are no approved HER2-targeted therapies available for patients with other HER2-overexpressing or HER2-mutated malignancies,” Bob Li, MD, senior author on the study said in a press release. 2 “Conventional therapies for these other HER2-overexpressing cancers tend to have limited efficacy and considerable side effects. Additional treatment options are urgently needed for…
